Surendra Bagaria, MD
Nuclear Cardiology · Sewell, NJNPI 1346232105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $854 and has fallen 63.2% since, to $314 in 2025.
Across 178 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$474
- Novartis$425
- E.r. Squibb & Sons, L.L.C.$309
- Impulse Dynamics (USA) Inc.$282
- Johnson & Johnson$249
- Lexicon Pharmaceuticals, Inc.$221
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $474 |
| Novartis | 27 | $425 |
| E.r. Squibb & Sons, L.L.C. | 8 | $309 |
| Impulse Dynamics (USA) Inc. | 3 | $282 |
| Johnson & Johnson | 18 | $249 |
| Lexicon Pharmaceuticals, Inc. | 6 | $221 |
| AstraZeneca | 15 | $199 |
| Merck | 12 | $169 |
| Boston Scientific | 3 | $167 |
| Atricure, Inc. | 1 | $142 |
| W. L. Gore & Associates, Inc. | 8 | $119 |
| Kowa Pharmaceuticals America, Inc. | 8 | $110 |
| Pfizer | 6 | $80 |
| Novo Nordisk | 6 | $75 |
| Bayer | 3 | $61 |
| Boehringer Ingelheim | 4 | $60 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| Astellas Pharma US Inc | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $41 |
| Akcea Therapeutics, Inc. | 2 | $38 |
| Edwards Lifesciences | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,447 in reported general payments places this provider in the 55th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 290 | $363,942 |
| XareltoRivaroxaban | 196 | $256,085 |
| EntrestoSacubitril/Valsartan | 66 | $99,936 |
| Repatha SureclickEvolocumab | 56 | $73,063 |
| JardianceEmpagliflozin | 27 | $39,477 |
| Praluent PenAlirocumab | 26 | $26,577 |
| Pitavastatin Calcium | 42 | $24,169 |
| Repatha SyringeEvolocumab | 15 | $21,505 |
| BrilintaTicagrelor | 17 | $17,369 |
| FarxigaDapagliflozin Propanediol | 13 | $16,457 |
| Metoprolol Succinate | 793 | $14,101 |
| Atorvastatin Calcium | 1,224 | $13,036 |
| Repatha PushtronexEvolocumab | 11 | $12,884 |
| Ezetimibe | 313 | $10,316 |
| VascepaIcosapent Ethyl | 17 | $8,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $363,942290 claims |
| Johnson & JohnsonXarelto | $249 | $256,085196 claims |
| NovartisEntresto | $425 | $99,93666 claims |
| Boehringer IngelheimJardiance | $60 | $39,47727 claims |
| AstraZenecaBrilinta, Farxiga | $199 | $33,82730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Sewell
- Howard WeinbergSewell$9K
- Bryan SaiaSewell$3K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
- Nasser ChaudhryCherry Hill$11K
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Scott GablerVoorhees$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.